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case report
Clinical and molecular spectrum 
of patients with 17b-hydroxysteroid 
dehydrogenase type 3 
(17-b-HSD3) deficiency
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SUMMARY
The enzyme 17b-hydroxysteroid dehydrogenase type 3 (17-b-HSD3) catalyzes the conversion of 
androstenedione to testosterone in the testes, and its deficiency is a rare disorder of sex devel-
opment in 46,XY individuals. It can lead to a wide range of phenotypic features, with variable 
hormonal profiles. We report four patients with the 46,XY karyotype and 17-b-HSD3 deficiency, 
showing different degrees of genital ambiguity, increased androstenedione and decreased tes-
tosterone levels, and testosterone to androstenedione ratio < 0.8. In three of the patients, diag-
nosis was only determined due to the presence of signs of virilization at puberty. All patients had 
been raised as females, and female gender identity was maintained in all of them. Compound 
heterozygosis for c.277+2T>G novel mutation, and c.277+4A>T mutation, both located within 
the intron 3 splice donor site of the HSD17B3 gene, were identified in case 3. In addition, ho-
mozygosis for the missense p.Ala203Val, p.Gly289Ser, p.Arg80Gln mutations were found upon 
HSD17B3 gene sequencing in cases 1, 2, and 4, respectively. Arq Bras Endocrinol Metab. 2012;56(8):533-9
SUMÁRIO
A enzima 17b-hidroxiesteroide desidrogenase tipo 3 (17-b-HSD3) catalisa a conversão de an-
drostenediona a testosterona nos testículos, e sua deficiência é uma forma rara de distúrbio 
do desenvolvimento do sexo em indivíduos 46,XY. A desordem apresenta um amplo espectro 
de características fenotípicas e de resultados de dosagens laboratoriais. Neste trabalho, são re-
latados quatro casos de deficiência da 17-b-HSD3 com cariótipo 46,XY, ambiguidade genital em 
diversos graus, androstenediona aumentada, testosterona diminuída, e relação testosterona e 
androstenediona < 0,8. Em três das pacientes, o diagnóstico foi suspeitado devido à presença 
de sinais de virilização na puberdade. Todos os pacientes foram criados como mulheres, e a 
identidade de gênero feminino foi mantida em todas elas. A heterozigose composta da muta-
ção nova c.277+2T>G e da mutação c.277+4A>T, ambas localizadas no sítio doador de splicing 
do íntron 3 do gene HSD17B3, foi identificada no caso 3. Além dessas, as mutações missense 
p.Ala203Val, p.Gly289Ser, p.Arg80Gln foram identificadas em homozigose pelo sequenciamen-
to do gene HSD17B3 dos casos 1, 2 e 4, respectivamente. Arq Bras Endocrinol Metab. 2012;56(8):533-9
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The isoenzyme 17b-hydroxysteroid dehydroge-nase type 3 (OMIM *605573, 17-b-HSD3), also 
known as 17-ketosteroid reductase, catalyses the con-
version of the weak androgen substrate, androstenedi-
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(T) in the testes. This conversion is essential for normal 
fetal development of male internal and external genita-
lia. The human gene, designated HSD17B3, contains 
11 exons and is located on 9q22 (1-3). 
17-b-HSD3 deficiency (OMIM #264300) is a rare 
autosomal recessive disorder form of male sex differ-
entiation, characterized by hypoplastic-to-normal in-
ternal genitalia, absent or hypoplastic prostate, testes 
within the inguinal region, and female external geni-
talia at birth (4-9). Mutations in the HSD17B3 gene 
are responsible for the disease, in which homozygous 
or compound heterozygous affected 46,XY individuals 
are usually born with female genitalia, and the disorder 
remains undetectable until puberty (10), when viriliza-
tion of the external genitalia occurs. This is probably 
due to the conversion of the abundant Δ4 to T by other 
extragonadal 17-b-HSD isoenzymes, or due to residual 
17-b-HSD3 activity (11). Many individuals raised as fe-
males develop a male gender identity, and decide to be 
reassigned as males after puberty (4-9,12,13). 
17-b-HSD3 deficiency in prepubertal patients is 
clinically indistinguishable from partial androgen in-
sensitivity syndrome, 5α-reductase type 2 deficiency, 
and other disorders of T biosynthesis. Diagnosis can 
be established by elevated Δ4 and low T serum levels 
that result in a T/Δ4 ratio lower than 0.8. In addi-
tion, there is a poor response to hCG stimulation 
test. In the absence of suggestive signs during child-
hood, the disorder will only be diagnosed at puberty 
upon virilization of affected individuals (7,14). 
To date, a total of 29 mutations in the HSD17B3 
gene have been identified (Figure 1), including 21 
missenses, one nonsense mutation, two frameshifs 
leading to downstream premature stop codon, four 
located at splice junctions leading to aberrant tran-
scripts, and one duplication of exons 3-10 (4,15,16). 
Here, we report the clinical and molecular pic-
tures of four cases of 17-b-HSD3 deficiency. 
MATERIALS AND METHODS 
Genomic DNA was obtained from peripheral blood 
by proteinase K/phenol extraction method (17). The 
11 exons and exon/intron junction sequences of 
HSD17B3 gene were amplified by polymerase chain 
reaction (PCR). Primers used for PCR were chosen 
with Prime 3 primer designing tool; primer sequences 
are available upon request. Purification of PCR prod-
ucts was carried out using the Wizard® SV Gel and 
PCR clean-up system (Promega, Madison, WI, USA). 
Direct PCR fragment sequencing with sense and an-
tisense primers was performed using Big Dye® Ter-
minator Cycle Sequencing Kit V3.1 Ready Reaction 
(ABI PRISM/PE Biosystems, Foster City, CA, USA). 
Sequences were obtained in an automatic sequencer 
ABI 3130 DNA Analyzer (ABI PRISM/PE Biosys-
tems), and were compared with the HSD17B3 nor-
mal sequence (ENSEMBL – ENSG00000130948) 
using Chromas (reduced version-free software) and 
CLC Sequence Viewer v.6.2 (free software).
Figure 1. HSD17B3 gene is represented with its 11 exons. Mutations found in 17-b-HSD3 deficiency are indicated. Black boxes highlight recurrent 
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CASE REPORTS
Case 1
A 16-year-old girl from Pariconha (Alagoas – North-
eastern region of Brazil) was referred to us due to 
genital ambiguity and virilization at puberty. She 
was born at term by cesarean section to a 48-year-
old mother, and weighted over 4.5 kg. Her parents 
were consanguineous (second cousins), and family 
history showed a sister with primary amenorrhea and 
absence of uterus, who had both gonadectomy and 
genitoplasty done during childhood. On physical ex-
amination, her weight and height were 68 kg and 
168.4 cm, respectively; genitalia presented a 5.7-
cm phallus and palpable gonads in labioscrotal folds 
with volumes of 15 cm3 and 10 cm3 for the right and 
the left gonad, respectively. A single perineal urethral 
opening with a short vagina were also observed. In 
addition, she presented facial hair and pubertal de-
velopment Tanner 3 for breasts, and Tanner 5 for 
pubic hair (Figures 2A and 2B). The karyotype was 
46,XY and laboratory data are shown in table 1. 
HSD17B3 gene sequencing revealed the homozy-
gous p.Ala203Val missense mutation within exon 9 
(Figure 3A). After psychological evaluation of the 
patient and the family, they decided to maintain the 
female gender. Bilateral gonadectomy and feminiz-
ing genitoplasty were performed, and hormonal 
replacement with estrogens was administrated. The 
analysis of both gonads indicated pubertal testes 
with discrete peritubular fibrosis. As she maintained 
the female gender, vaginal dilation will be performed 
as soon as she decides to initiate sexual activity.
Case 2
A 4‐year‐old girl, from Oliveira dos Brejinhos (Ba-
hia – Northeastern region of Brazil), was referred 
to us to investigate genital ambiguity with palpable 
gonads. She was the second child of non-consangui-
neous parents, and was born at term after an unevent-
ful pregnancy. At physical examination, her weight 
was 16.2 kg and height 102 cm. A 3.7-cm phallus, 
single perineal opening, labioscrotal fusion, and bi-
lateral palpable gonads within inguinal region were 
observed. Cytogenetic analysis indicated a 46,XY 
karyotype. Laboratory data are shown in table 1. 
HSD17B3 gene sequencing showed homozygosis 
for the p.Gly289Ser substitution in exon 11 (Figu-
re 3B). Her family decided to maintain the female 
gender. Therefore, gonadectomy, clitoroplasty, and 
introitoplasty were performed. Histological analysis 
of the gonads showed normal pre‐pubertal testes.
Case 3
A 13‐year‐old girl from São Luís (Maranhão –North-
eastern region of Brazil) was referred to us due to 
signs of virilization such as acne, hirsutism, voice 
deepening, and phallus enlargement since the age of 
11. She was born at term after an uneventful preg-
nancy. Her parents were healthy, non-consanguin-
eous, and from small cities Maranhão State (For-
tuna and Buriti Bravo). She had two sisters, both 
with telarche, and without signs of virilization, and 
one brother without sex ambiguity. On physical ex-
amination, the patient was 164 cm tall and weighed 
59.8 kg. Her breasts were Tanner stage 1. She had 
increased hair on the abdomen and face, phallus en-
largement (3.7 cm), and the skin of labioscrotal folds 
were pigmented and rugged. Pubic hair was Tanner 
stage 4. Her vagina ended in a 3-cm pouch, and no 
gonads were palpable (Figures 2C and 2D). Karyo-
type was 46,XY. Results of hormonal evaluation are 
shown in table 1. MRI of the abdomen and pelvis 
did not show an uterus or a prostate. However, sem-
inal vesicles were identified, and both gonads were 
found at the inguinal region. HSD17B3 gene se-
quencing showed heterozygosis for two nucleotide 
changes within intron 3 splice donnor consensus 
sequence, c.277+4A>T, and the novel c.277+2T>G 
(Figure 3C). The analysis of the family indicated that 
the first variant was inherited from her father, and 
the second from her mother (data not shown). After 
female gender identity was confirmed by long-term 
psychological evaluation, video laparoscopy was per-
formed to remove the gonads, and estrogen replace-
ment therapy was initiated, followed by vaginal dila-
tion. Histologic examination of both gonads showed 
bilateral testes with slight peritubular fibrosis, germ-
cell aplasia, and Leydig cell hyperplasia, without evi-
dence of malignancy. 
Case 4
A 14‐year‐old girl from Alto do Araguaia (Mato 
Grosso – Central-Western region of Brazil) was 
brought to us due to genital ambiguity and viriliza-
tion at puberty. She was the second child of a con-
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showed a 2-year-old female maternal cou sin who 
presented clitoromegaly, and a 12-year-old female 
paternal cousin with hirsutism. Upon physical ex-
amination, the patient was 160 cm tall and weighed 
41.4 kg. She had a 4.5-cm phallus, a single perine-
al opening, partial fusion of labioscrotal folds with 
pigmentation, and bilateral palpable gonads in the 
lower third of inguinal canal. Facial, axillary, ab-
dominal, and pubic hair (Tanner 3) were observed, 
as well as Tanner 3 breast development. Karyotype 
was 46,XY. Hormonal evaluation data are shown in 
table 1. Pelvic ultrasonography did not show a ute-
rus or a prostate. Genitography showed a urogenital 
sinus with a short vagina. HSD17B3 gene sequenc-
ing showed homozygosis for p.Arg80Gln mutation 
in exon 3 (Figure 3D). The patient decided to main-
tain the female gender; therefore, gonadectomy and 
feminizing genitoplasty were performed. Histologi-
cal gonadal analysis indicated normal pubertal testes. 
Estrogen replacement therapy was initiated, and the 
patient decided to postpone vaginal dilation.
Figure 2. External genitalia of patients with HSD17B3 deficiency. Case 1 









Figure 3. Parts of the eletropherograms obtained for HSD17B3 gene 
sequencing: A) Homozygous GCG>GTG nucleotide change within exon 9 
identified in case 1; this substitution causes the replacement in residue 
203, usually alanine, by valine (p.Ala203Val). B) Homozygous GGT>AGT 
nucleotide change within exon 11 identified in case 2; this substitution 
causes the replacement in residue 289, usually glycine by serine 
p.Gly289Ser. C) Compound heterozygosis for c.277+2T>G and 
c.277+4A>T nucleotide changes in case 3, which were inherited from the 
mother and the father, respectively (data not shown); the two mutations 
are within the donor splice site consensus sequence of intron 3; the empty 
red arrow indicates the beginning of IVS3 at exon 3/intron 3 boundary. D) 
Homozygous CGG>CAG nucleotide change within exon 3 identified in 
case 4; this substitution causes the replacement in residue 80, usually 
arginine by glutamine (p.Arg80Gln). 
DISCUSSION
We report here four cases of 17-b-HSD3 deficiency, 
a rare disorder that was described for the first time 
in 1971 (18,19). It is a rare form of 46,XY DSD 
that affects testosterone biosynthesis (4). Its preva-
lence is higher among the Arab population, ranging 
from 1:100 to 1:300, due to a high frequency of 
consanguineous marriages (20). Two out of the four 
cases described here were born to consanguineous 
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for HSD17B3 mutations. On the other hand, case 2, 
who has non-consanguineous parents, also showed 
a homozygous mutation in the HSD17B3 gene. In 
this case, the patient and her parents were born at a 
small city of the countryside of the State of Bahia. 
Different HSD17B3 gene mutations confer a wide 
range of phenotypic characteristics to 46,XY affected 
individuals. These may vary from predominantly fe-
male genitalia, as in case 3; to mild virilized female 
genitalia, as in case 2; to evident genital ambiguity 
with palpable gonads, as in cases 1 and 4; to pre-
dominantly male genitalia with microphallus and hy-
pospadias (4-8). This variability in phenotypes may 
correlate with partial activity of mutated 17-b-HSD3 
in the testes, or to an extragonadal conversion of Δ4 
to T by other 17-b-HSD isoenzymes (11).
As the most common clinical presentations of 
17-b-HSD3 deficiency are female or mild virilized 
female genitalia, most patients do not have the diag-
nosis of 46,XY DSD at birth, and are registered and 
raised as females (4,5,8). Therefore, diagnosis is only 
established at puberty for most patients (4-8). Con-
versely, some cases may be diagnosed early, because 
they seek medical care during childhood due to some 
degree of virilization with palpable gonads (4,5,7). 
If 17-b-HSD3 deficiency is not diagnosed in 
childhood, and gonadectomy is not performed, pa-
tients may present virilization at puberty (4,5,7). 
Main signs of virilization are increased hair growth 
all over the body and face, deepening of the voice, 
and android fat distribution, in addition to phallus 
elongation reaching 5-8 cm in length, which may 
also be observed in response to peripheral T con-
version. However, the phallus will always be shorter 
than a normal-sized penis (4,5,7). 
The diagnosis of 17-b-HSD3 deficiency may be 
suspected upon laboratory investigation, and may 
be confirmed with molecular analysis. As verified in 
all cases reported here, patients have, respectively, 
high and low to normal Δ4 and T serum concen-
trations (4,5,7). When T/Δ4 ratio is less than 0.8, 
17-b-HSD3 deficiency is suggested (7,14). The lit-
erature also refers to increased serum concentrations 
of DHEA and DHEA sulfate (4,5,7). However, 
these elevated values are not always observed.
The mutation p.Arg80Gln identified in case 4 is the 
most common one in Mediterranean (21) and Bra-
zilian patients (6). McKeever and cols. (22) demon-
strated that p.Arg80Gln causes a significant decrease 
in the rate of enzymatic reaction leading to approxi-
mately 5% of residual enzyme activity, and a 1/60 re-
duction in the binding affinity of the mutant protein 
to NADPH cofactor. Therefore, it is suggested that 
the R in residue 80 of the protein structure should be 
critical in maintaining appropriate levels of enzymatic 
activity, and to promote normal human male devel-
Table 1. Hormonal profile of four cases with HSD17B3 deficiency
Case 1 Case 2 Case 3 Case 4
Male reference range
(12 – 19 yr)Age (years) 16 4 13 14
Puberty + - + +
LH (IU/L) 12.1 0.4 16.0 10.5 0.5 - 5.3
#0.1 - 1.2
FSH (IU/L) 7.4 2.0 6.7 8.7 1.4 - 18.1
#0.8 - 2.3
T (ng/mL) 4.2 0.8* 3.4 3.1 0.1 - 5.0
Δ4 (ng/mL) 6.8 1.3* 6.5 4.8 0.7 - 1.9
DHT (ng/mL) 0.49 0.21* 0.42 0.58 0.25 - 1.20
E1 (pg/mL) 32.1 NP 41.0 42.7 17.0 - 44.0
E2 (pg/mL) 20.9 NP 25.8 22.2 < 50.0
DHEA sulfate (μg/mL) 3.8 1.9 2.5 3.9 1.0 - 4.2
T/DHT ratio 8.6 3.8* 8.1 5.3 < 10.0
T/Δ4 ratio 0.62 0.61 0.50 0.65 > 0.8
E2/E1 ratio 0.65 NP 0.63 0.52 -
* After 3 consecutive days of 1,500 IU of intramuscular of human chorionic gonadotropin;
# pre-pubertal male reference range; Δ4: androstenedione; E1: estrone; E2: estradiol; 
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opment. This mutation was first described in a Pales-
tinian family from the Gaza Strip (20). Further, it was 
also identified in Brazilian families with no Palestin-
ian ancestry, and of probable Portuguese origin (6). 
However, its recurrence, not only in patients of Arab 
origin, but also in Dutch patients, was reported for 
individuals who were homo- or heterozygous for this 
mutation (5). Therefore, p.Arg80Gln may represent 
a founder effect, common among Arabs from differ-
ent regions of Israel, Lebanon, and Syria (23). This 
fact led to the hypothesis that it has been introduced 
in Portugal and Spain by Phoenicians who migrated 
from Syria, Lebanon, and Israel around 750 B.C. 
(24,25). Its introduction in the Netherlands could 
have occurred during the Spanish domination in the 
sixteenth and seventeenth centuries and, in Brazil, by 
Portuguese colonizers and during the Dutch invasion 
of the Northeastern region of the country.
The p.Ala203Val mutation identified in case 1 was 
first described by Geissler and cols. (26), in a patient 
from São Paulo – Brazil. This mutation was assayed 
for the ability to convert Δ4 into T, and it complete-
ly inactivated the enzyme 17-b-HSD3, indicating a 
good correlation with the phenotype of case 1.
Moghrabi and cols. (27) reported the missense 
substitution p.Gly289Ser (SNP – CM023631). 
This mutation has been considered a polymorphism 
since it is frequent in all populations reported in the 
screening of 1,000 genomes (28). It also did not al-
ter the in vitro enzymatic activity. However, it was 
identified in a compound heterozygous patient who 
also carried the well-known deleterious p.Asn130Ser 
mutation. It was supposed that this patient carried 
alterations in regulatory regions of the HSD17B3 
gene that may explain the phenotype (5). In addi-
tion, p.Gly289Ser amino acid substitution has been 
associated with increased risk of developing prostate 
cancer, and to hypospadias in individuals carrying 
the S289 allele in homozygosis, once mRNA expres-
sion levels were significantly lower for the mutant 
S289 than for the wild-type G289, indicating that 
it may not be as neutral as it had been initially con-
sidered (29,30). Since we did not evaluate either 5’ 
or 3’ regulatory regions, we can speculate that the 
homozygous p.Gly289Ser in case 2 may be associ-
ated with the phenotype, and some other nucleotide 
change in regulatory regions could act synergistically 
with the mutation. 
Case 3 was found to be compound heterozy-
gous for two nucleotide changes affecting intron 3 
splice donor region. The c.277+4A>T mutation was 
reported in 1996 by Andersson and cols. (9), who 
identified it in homozygosis in three families, and in 
heterozygosis in two other families. Those results 
indicated it as one of the most prevalent mutations 
found in subjects with 17-b-HSD3 deficiency. It is 
located within the intron 3 canonical splice donor 
site, and was shown to disrupt normal splicing by 
Boehmer and cols. (5), who analyzed the HSD17B3 
cDNA prepared from testis mRNA of a homozygous 
patient. The result of cDNA sequencing showed a 
transcript where exon 3 had been skipped and, in 
minor amounts, a transcript with deletion of both 
exons 3 and 4 (5,31). 
The mutation c.277+4A>T is found in popula-
tions worldwide, including Dutch, Germans, white 
Australians and white Americans, who share the same 
marker genotype, and are likely to be identical by de-
scent (5). The c.277+2T>G mutation was also identi-
fied in case 3. It changes the almost invariant GT at 
the splice donor site to GG in intron 3. This mutation 
was identified here for the first time, and it probably 
suppresses the normal splicing so that it can either ac-
tivate a cryptic splice site, or lead to exon 4 skipping. 
The in silico search for splicing sites using the online 
Splice Site Prediction NNSPLICE 0.9 version indi-
cated that the mutation eliminated the normal donor 
splice at that position (data not shown). As testicu-
lar samples are not accessible for in vitro studies, the 
construction of mini-genes will be an alternative to 
test an aberrant splicing process in this case.
Patients with 17-b-HSD3 deficiency undergo 
virilization if gonadectomy is not performed before 
puberty, and some may adopt the male gender (4-
8,12,13). Such a decision usually occurs in late ado-
lescence or early adulthood, and the frequency varies 
between 39% and 64% (13). The explanation for the 
male option to occur is still unclear. Conversely, most 
patients who undergo prepubertal gonadectomy re-
main in the female gender (4-8). According to the 
literature, patients who choose to remain as females 
must undergo gonadectomy not only to avoid virili-
zation, but also because of the 28% risk of malignant 
germ cell tumors (32). These patients should receive 
estrogen replacement therapy for the development 
of secondary sexual characteristics (4). All patients 
reported here, even those diagnosed at puberty, de-
cided to maintain female identity after psychological 
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 In conclusion, we report mutations in HSD17B3 
gene, including the novel c.277+2T>G mutation, in 
four cases of 17-b-HSD3 deficiency with different 
clinical laboratorial and presentations.
Disclosure: no potential conflict of interest relevant to this article 
was reported.
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